PropThink: Five Months After Approval, DSCO Needs a Partnership; Gains From Upgrade Likely Temporary

PropThink: Five Months After Approval, DSCO Needs a Partnership; Gains From Upgrade Likely Temporary

ID: 178691

(Thomson Reuters ONE) -


Discovery Laboratories (NASDAQ:DSCO) has moved up 28% on trading momentum
following a Buy rating on the 24th. The company's lead product, Surfaxin, was
approved by the FDA in March for the prevention of Respiratory Distress Syndrome
(RDS) in infants. Now that the company has an approved product ready for
commercialization, investors will be looking for evidence of revenue growth. The
company guides for a product launch in the fourth quarter of 2012 for Surfaxin
as well as its Afectair ventilator medication device. A commercialization
partner for the products, however, has yet to be found. In its 2Q earnings
report, management stated that they are actively seeking, and in discussion
with, potential collaborators, which will help secure DSCO's future through
milestone and royalty revenue. The company raised $42MM through a share offering
in March and, according to management, hopes to avoid further shareholder
dilution.

To read the rest of this article, click here.

About PropThink

PropThink is an intelligence service that delivers long and short trading ideas
to investors in the healthcare and life sciences sectors. Our focus is on
identifying and analyzing technically-complicated companies and equities that
are grossly over or under-valued. We offer daily market coverage, weekly feature
stories, and a newsletter to investors who subscribe on PropThink.com. To learn
more visit us at http://www.propthink.com.




This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: PropThink via Thomson Reuters ONE




[HUG#1637047]




Weitere Infos zu dieser Pressemeldung:
Unternehmensinformation / Kurzprofil:
drucken  als PDF  an Freund senden  PropThink: Scale Into HALO In Front Of Roche 'Investor Day'; Insiders Still Buying KONE to provide eco-efficient People Flow solutions to Scandinavia's largest mall
Bereitgestellt von Benutzer: hugin
Datum: 29.08.2012 - 15:11 Uhr
Sprache: Deutsch
News-ID 178691
Anzahl Zeichen: 2129

contact information:
Town:

New York



Kategorie:

Business News



Diese Pressemitteilung wurde bisher 179 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"PropThink: Five Months After Approval, DSCO Needs a Partnership; Gains From Upgrade Likely Temporary"
steht unter der journalistisch-redaktionellen Verantwortung von

PropThink (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von PropThink



 

Werbung



Facebook

Sponsoren

foodir.org The food directory für Deutschland
Informationen für Feinsnacker finden Sie hier.

Firmenverzeichniss

Firmen die firmenpresse für ihre Pressearbeit erfolgreich nutzen
1 2 3 4 5 6 7 8 9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z